News | May 22, 2024
AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
Launch of 20 new medicines expected by 2030
Launch of 20 new medicines expected by 2030
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing in Malaysia's largest clinic operator to expand the healthcare business
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Subscribe To Our Newsletter & Stay Updated
